Results 211 to 220 of about 59,389 (246)

Tumorigenicity decrease in Bcl-xL deficient MDCK cells ensuring the safety for influenza vaccine production. [PDF]

PLoS One
Zheng J, Li B, Jia L, Zhang J, Gong Z, Le Y, Nian X, Li X, Liu B, Yu D, Zhang Z, Li C.   +11 more
europepmc   +1 more source

Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis

, 2009
Justine Rudner, Simon J. Elsaesser, Arndt‐Christian Müller, Claus Belka, Verena Jendrossek   +4 more
openalex   +2 more sources

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non-Canonical Amino Acids for Coinhibition of MCL-1 and BCL-xL in Acute Myeloid Leukemia. [PDF]

Adv Sci (Weinh)
Wang Z, Lai R, Wang X, Chen X, Zhou Y, Li S, Qiu X, Zeng Z, Yuan J, Mao J, Chen Z, Wang J.   +11 more
europepmc   +1 more source

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting. [PDF]

Discov Oncol
Li F, Chen Y, Zhuang H, Pei R, Lu Y, Chen D, Li S, Ye P, Lian J, Lu Y.   +9 more
europepmc   +1 more source

A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice. [PDF]

Nat Aging
Yang Y, Jn-Simon N, He Y, Sun C, Zhang P, Hu W, Tian T, Zeng H, Basha S, Huerta AS, Sun LZ, Yin XM, Hromas R, Zheng G, Pi L, Zhou D.   +15 more
europepmc   +1 more source

Part 1: Troglitazone analogues as cyclin D1 ablative agents: the potential drugs for breast cancer therapy Part 2: Vitamin E and its analogues induce apoptosis in prostate cancer cells in part through inhibition of Bcl-2/Bcl-xL functions

, 2005
Jui‐Wen Huang
openalex   +1 more source

Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis. [PDF]

Oncol Rep
Kato A, Takahashi H, Asai H, Uehara S, Harata S, Fujii Y, Watanabe K, Yanagita T, Suzuki T, Ushigome H, Shiga K, Yamakawa Y, Ogawa R, Mitsui A, Matsuo Y, Takiguchi S.   +15 more
europepmc   +1 more source

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients. [PDF]

Int J Mol Sci
Chang LC, Yin MT, Laird GM, Ritter KD, Shah JG, Debnath AK.   +5 more
europepmc   +1 more source

The Innate Immune System and the TRAIL-Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females. [PDF]

Cancer Res
May L, Hu B, Jerajani P, Jagdeesh A, Alhawiti O, Cai L, Semenova N, Guo C, Isbell M, Deng X, Faber AC, Pillappa R, Bandyopadhyay D, Wang XY, Neuwelt A, Koblinski J, Bos PD, Li H, Martin R, Landry JW.   +19 more
europepmc   +1 more source

HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. [PDF]

Cell Death Differ
Alcon C, Kovatcheva M, Morales-Sánchez P, López-Polo V, Torres T, Puig S, Lu A, Samitier J, Enrich C, Serrano M, Montero J.   +10 more
europepmc   +1 more source